Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 8/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714155 | 0.92 | PRF1 (0.41) | PRF1ACHEPOLQPDE4DMAOA | |
| SCHEMBL2584274 | 0.89 | PRF1 (0.42) | PRF1PDE4DCYP3A4 | |
| SCHEMBL2591212 | 0.87 | PRF1 (0.44) | PRF1ACHEPDE4DCYP3A4 | |
| SCHEMBL2591538 | 0.84 | PRF1 (0.38) | PRF1PDE4DCYP3A4 | |
| SCHEMBL7714379 | 0.83 | GSK3B (0.39) | PRF1POLQ | |
| SCHEMBL2591559 | 0.82 | PDE4D (0.41) | PRF1ACHEPDE4DCYP3A4 | |
| SCHEMBL2590966 | 0.82 | PDE4D (0.38) | PRF1PDE4DCYP3A4 | |
| SCHEMBL2592725 | 0.82 | PDE4D (0.41) | PRF1POLQPDE4DMAOAMAOB | |
| SCHEMBL2588578 | 0.80 | PRF1 (0.43) | PRF1ACHEPDE4DCYP3A4 | |
| SCHEMBL2593335 | 0.80 | PDE4D (0.41) | PRF1ACHEPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011134468-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-11-03 | — | — | WO | disclosed |